Get Stockpiling Now, Industry Urges UK Government
Industry Warns Of More Shortages As EU Talks Falter
An internal memo has revealed the extent of the pharmaceutical industry’s worries over serious product shortages amid the COVID-19 pandemic and the possibility that the UK and the EU will fail to agree a trade deal by the end of 2020.
You may also be interested in...
Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.